Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 6/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.62 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CASR | P41180 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9782591 | 1.00 | ADRB2 (0.62) | ADRB2ADRB1ADRB3CYP2D6CA1 | |
| SCHEMBL11067846 | 1.00 | ADRB2 (0.62) | ADRB2ADRB1ADRB3CYP2D6CA1 | |
| SCHEMBL23751082 | 0.83 | CA1 (0.62) | ADRB1CA1CA2CA7CA9 | |
| SCHEMBL22574150 | 0.83 | CA1 (0.62) | ADRB1CA1CA2CA7CA9 | |
| SCHEMBL15623805 | 0.83 | ADRB2 (0.50) | ADRB2ADRB1ADRB3CYP2D6CA1 | |
| SCHEMBL10814311 | 0.82 | ADRB2 (0.78) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL10814431 | 0.82 | ADRB2 (0.78) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL10814305 | 0.82 | ADRB2 (0.78) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| Hydrochloric Acid SCHEMBL11684567 | 0.81 | ADRB2 (0.76) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| Hydrochloric Acid SCHEMBL11593853 | 0.81 | ADRB2 (0.76) | ADRB2ADRB1ADRB3CYP2D6PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | ADRB2 4055/4885ADRB1 4181/4885ADRB3 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.